{
    "clinical_study": {
        "@rank": "21912", 
        "brief_summary": {
            "textblock": "To evaluate safety, pharmacokinetics, immunologic parameters and neurocognitive data for\n      three dosages of AS-101 in combination with zidovudine (AZT) in patients with AIDS or AIDS\n      related complex (ARC)."
        }, 
        "brief_title": "A Safety, Pilot Pharmacokinetics and Neurocognitive Study of AS-101 in Combination With Zidovudine in AIDS/ARC Patients", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Required:\n\n          -  Zidovudine (AZT).\n\n          -  Aerosolized pentamidine for Pneumocystis carinii pneumonia (PCP) prophylaxis.\n\n          -  Allowed ONLY with permission of the Wyeth-Ayerst medical monitor:\n\n          -  Standard therapy for infections that develop during the study period.\n\n          -  Oral acyclovir.\n\n          -  Nystatin.\n\n          -  Ketoconazole.\n\n          -  Immunomodulators.\n\n          -  Specific therapy for malignancies (including Kaposi's sarcoma).\n\n        Patients must have the following:\n\n          -  Diagnosis of AIDS or AIDS related complex (ARC).\n\n          -  Provide informed written consent.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Active opportunistic infection or malignancy requiring treatment at study entry.\n\n          -  Prior history of psychiatric illness or head injury which in the judgment of the\n             neuropsychologist would impair interpretation of the neurocognitive data.\n\n          -  Evidence of central nervous system (CNS) opportunistic infection or malignancy.\n\n          -  Serious underlying medical problems, including insulin- dependent diabetes mellitus,\n             unstable ASHD (atherosclerotic heart disease) or uncontrolled hypertension, which may\n             complicate interpretation of treatment results.\n\n          -  Dementia.\n\n          -  Evidence of = or > 2 + proteinuria at study entry.\n\n        Concurrent Medication:\n\n        Excluded without permission of the Wyeth-Ayerst medical monitor:\n\n          -  Immunomodulators.\n\n          -  Specific therapy for malignancies (including Kaposi's sarcoma).\n\n        Patients with the following are excluded:\n\n          -  Active opportunistic infection or malignancy requiring treatment at study entry.\n\n          -  Prior history of psychiatric illness or head injury which in the judgment of the\n             neuropsychologist would impair interpretation of the neurocognitive data.\n\n          -  Evidence of conditions listed in the Patient Exclusion Co-existing Conditions.\n\n          -  Active substance abuse.\n\n          -  Unlikely or unable to comply with the requirements of the protocol.\n\n        Prior Medication:\n\n        Excluded within 8 weeks of study entry:\n\n          -  Immunomodulators.\n\n          -  Antiviral therapy, except zidovudine.\n\n          -  Excluded within 2 weeks of study entry:\n\n          -  Intravenous or oral acyclovir.\n\n          -  Excluded within 3 months of study entry:\n\n          -  Ribavirin.\n\n        Required:\n\n          -  Zidovudine at a dose of = or > 1000 mg/day for at least 6 weeks prior to study entry.\n\n        Active substance abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002013", 
            "org_study_id": "045C", 
            "secondary_id": "753A-109-US"
        }, 
        "intervention": [
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "AS-101", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Zidovudine", 
                "Ammonium trichloro(dioxoethylene-O,O'-)tellurate"
            ]
        }, 
        "keyword": [
            "Drug Therapy, Combination", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "ammonium trichloro(dioxoethylene-O,O'-)tellurute", 
            "Zidovudine"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "900331084"
                }, 
                "name": "Los Angeles County - USC Med Ctr"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Safety, Pilot Pharmacokinetics and Neurocognitive Study of AS-101 in Combination With Zidovudine in AIDS/ARC Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "reference": {
            "citation": "Laporate JP, Frottier J, Dormont D, Imbert JC, Albeck M, Najman A. As 101 in association with azt in AIDS patients: a phase I pilot study. Int Conf AIDS. 1989 Jun 4-9;5:405 (abstract no WBP320)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002013"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Wyeth is now a wholly owned subsidiary of Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 1990"
    }, 
    "geocoordinates": {
        "Los Angeles County - USC Med Ctr": "34.052 -118.244"
    }
}